EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.
EGenesis has raised $191.0M in total funding. The most recent round was Series D. The last funding was announced in September 2024.
EGenesis's investors include Khosla Ventures, ARCH Venture Partners, Lux Capital, Samsara BioCapital, Catalio Capital Management.
EGenesis is headquartered in Cambridge, United States.
EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.
EGenesis is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EGenesis — Funding & Investors." VCBacked, September 4, 2024, https://www.vcbacked.co/company/egenesis. Accessed July 19, 2026.
VCBacked. (2024). EGenesis — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/egenesis
{{cite web |title=EGenesis — Funding & Investors |url=https://www.vcbacked.co/company/egenesis |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated